Skip to Content

Sitagliptin Promising Addition for Preventing Acute GVHD

THURSDAY, Jan. 7, 2020 -- For patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation, sitagliptin combined with tacrolimus and sirolimus results in a low incidence of grade II to IV acute graft-versus-host disease (GVHD) by day 100, according to a study published in the Jan. 7 issue of the New England Journal of Medicine.

Sherif S. Farag, M.D., Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a phase 2 clinical trial to examine the reduction in incidence of grade II to IV acute GVHD from 30 percent to no more than 15 percent by day 100 with sitagliptin plus tacrolimus and sirolimus. Thirty-six patients received myeloablative conditioning followed by mobilized peripheral-blood stem cell transplants from matched related or unrelated donors.

The researchers found that by day 100, acute GVHD occurred in two of 36 patients. The incidence of grade II to IV GVHD and of grade III or IV GVHD was 5 and 3 percent, respectively. At one year, nonrelapse mortality was zero. The one-year cumulative incidence of relapse was 26 percent, and for chronic GVHD, it was 37 percent. At one year, GVHD-free, relapse-free survival was 46 percent. Toxic effects were similar to those seen in patients undergoing allogeneic stem cell transplantation.

"Inhibition of dipeptidyl peptidase 4 should be further investigated in randomized trials that compare sitagliptin with current standard GVHD prophylaxis regimens," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Stem Cell Transplant May Slow Disability in Multiple Sclerosis

THURSDAY, Jan. 21, 2021 -- For patients with multiple sclerosis (MS), autologous hematopoietic stem cell transplantation (aHSCT) may prevent worsening of disability, according to...

Stem Cell Infusions Investigated for Treatment of COVID-19 ARDS

FRIDAY, Jan. 15, 2021 -- Researchers are exploring the potential immunomodulatory and anti-inflammatory effects of umbilical cord mesenchymal stem cell (UC-MSC) infusions for...

ASH: Stem Cell Transplant Benefits Older Adults With MDS

TUESDAY, Dec. 8, 2020 -- Among older patients with myelodysplastic syndrome (MDS), survival rates are better for those undergoing allogeneic hematopoietic cell transplantation...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.